7th October 2024

REVERSE DOSIMETRY IN TKP LATE TO RECONSTRUCT EXP OS URE DISTRIBUTIONS USING BIOMONITORING DATA

Jean Lou CM Dorne, Lead expert in NAMs Jose Cortinas-Abrahantes, Alicia Paini Senior Scientific Officers Keyvin Darney, ANSES, Senior Scientific Officer



OUTLINE

TKPlate 1.0 : Introduction and General Workflow

TKPlate : Reverse Dosimetry

Caffeine Case Study


Current and Future perspectives



TKPlate General Workflow and Reverse Dosimetry



TKPLATE 1.0: INFO PAGE AND GENERAL WORKFLOW



TKPlate Workflow

MixTox Module



RELEVANCE OF TKPLATE 1.0 TO EFSA'S REMIT

Relevance to EFSA

- All Units dealing with chemicals at EFSA
- Supports use of NAMs@EFSA without testing: generate TK TD profiles, Id data gaps etc..
- Pesticides, food and feed additives, contaminants, novel foods etc.
- PBK/QIVIVE particularly relevant to pesticides (e.g. Developmental Neurotoxicity).

Input parameters

- Data from regulatory dossiers (i.e. kinetic data/dose response data for regulated products
- Data from literature
- Previous assessments
- Public databases such as EFSA'sOpenFoodTox, US-EPA CompToxChemicals dashboard, ECHA's REACH Database



WHAT CAN TKPLATE 1.0 DO FOR RISK ASSESSMENT AS A NAM TOOL ?

Human and animal PBK models in Annex of 2021 OECD guidance, described/validated with reporting template

Forward Dosimetry (From exposure to internal dose) for humans and animals (test/farm)

- Predict through simulations elimination and residues of chemicals in blood/target organs:
- ✓ In vivo data (oral route as well as multiple route (oral, dermal, inhalation))
- ✓ In vitro data through QIVIVE models
- Comparison predictions/ experimental data for kinetic profiles/ residues in fluids/organs
- Inter-species comparisons

Reverse Dosimetry (From internal to external dose)

- Recalculate exposure based on biomonitoring data
- Can be used to derive human biomonitoring guidance values (HBM-GVs) i.e. assess chemical exposure levels measured in HBM studies in a health risk assessment context.

TK PLATE 1.0 : PUBLICATION AND ASSOCIATED OUTPUTS

Further development of a web-based open-source platform for Toxicokinetic and Toxicodynamic modelling: TKPlate 1.0

Han Bossier, Joris Chau, Machteld Varewyck, Stephanie Vergucht and Tobias Verbeke

Open Analytics NV

Technical Report

APPROVED: 8 November 2023 doi:10.2903/sp.efsa.2023.EN-8441

User Guide for TKPlate 1.0: An open access platform for implementing new approach methodologies in chemical risk assessment through toxicokinetic and toxicodynamic modelling

European Food Safety Authority (EFSA), Han Bossier, José Cortiñas-Abrahantes, Keyvin Darney, Fotis Spyropoulos, Leonie S Lautz, Pierre André Billat, Rémy Beaudouin, Florence Zeman, Cléo Bodin, Jean Lou CM Dorne

pproved: 12 October 2023	
--------------------------	--

OOI: 10.2903/j.efsa.2023.e211101

EDITORIAL



TKPlate 1.0: An Open-access platform for toxicokinetic and toxicodynamic modelling of chemicals to implement new approach methodologies in chemical risk assessment

Technical Report

APPROVED: 8 November 2023 doi: 10.2903/sp.efsa.2023.EN-8440



Applications of TKPlate 1.0 for toxicokinetic and toxicodynamic modelling of chemicals: Case Studies

European Food Safety Authority (EFSA), Han Bossier, Fotis Spyropoulos, Keyvin Darney, Leonie S Lautz, Pierre André Billat, Rémy Beaudouin, Florence Zeman, Cléo Bodin, José Cortiñas-Abrahantes, Jean Lou CM Dorne






TKPlate: Reverse Dosimetry



REVERSE DOSIMETRY MODULE : WHAT THE BODY DOES TO THE CHEMICAL : FROM THE INSIDE TO THE OUTSIDE



Y

INTRODUCTION TO REVERSE DOSIMETRY

- **Definition: Reconstruct exposure distribution from internal measured concentrations**
- Key Purpose: Allows more accurate interpretation HBM data identifying external exposure sources.
- Example: Select kinetic/PBK model to simulate external dose for a given exposure scenario

<u> </u>		v 1.0.23 - Manual - Report new issue
TKPlate Interactive M	lodelli	ng Platform 001 10.5281/zerodo.10068769
fo Input Forward Dosimetry Reverse Dosimetry		dynamic DEB MixTox Report
Biomonitoring data	0	Input Data Posterior distribution Time-concentration curves Analysis logs
Selected model (Input tab):		Upload Data
bbtk1cpt		General Information
Select model compartment		 File needs to be in a .csv format. One column needs to be called "time" and contains the time points of the data.
Coompartment	•	3. Another column needs to be called "value" and contains the observed data of the compartment selected at the left hand side in milligram.
		 For the 1 compartment and farm animal model, fictional data is available. In these cases, click on "Load fictional data". Warning: data and plots are automatically reset whenever a new model is chosen in the Input tab!
Time unit of measured data:		Upload Data (CSV)
◯ hour ● min ◯ sec		Browse No file selected Clear data Load fictional data
Exposure time (same unit as above):	7	
0.5		
0.5		
Markov Chain Monte-Carlo settings	0	
Choose prior distribution for exposed dose (mg/ kg BW / mir		
Truncated Normal	•	
Mean SD min max		
5 1000 0 50		
Number of independent chains:		
1 2 3 4 5 6 7 8 9 10 11		
For each chain, set number of:		
sampling iterations burn-in (i.e. discarded) 2000 iterations		
1000		
Use custom starting seeds.		
(Re-)run MCMC!		



STEPS IN REVERSE DOSIMETRY

- **1. Select PBK Model:** Define set of input parameters (chemical-specific and physiological parameters) to simulate kinetic processes (select model)
- **2. Biomonitoring Input:** Biomonitoring data (e.g., blood) measuring concentrations of chemicals, compartment of interest, exposure scenario and MCMC settings.
- **3. Output:** Run simulations, diagnostic of model are presented, checking convergence and other metrics to support model evaluation. In addition, posterior distribution of the attributable external dose based on previous inputs as well as a plot of observed vs fitted biomonitoring data are provided.



STEPS IN REVERSE DOSIMETRY: PBPK MODEL AND PARAMETERS

1.1. PBPK Model inputs: Defining model type, species, chemical and exposure setting

Info	Input	Forward Dosimetry	Reverse Dosimetry	Toxico
Inpu				
Mode	el Type			
Chang	ing the m	odel resets all filled-in par	ameter values.	
1-cor	mpartment			•
Spec	ies			
1.1		ecies resets all filled-in p	arameter values.	
Hum				
	an			-
Cher	nical			
() Ava	ilable opt	ions for chemical selection	n	
Mela	tonin			•
-	Jser Defir	ed Chemical		
D Sho	W EPA C	ompTox Search URL		
_				(?)
		Settings		Ŭ
Dose				
_	®mg O	microg		
Time		nin Osec		
	sure Metr		Contraction DW(14)	
O abs	olute (mg) O dose (mg/kg BW)	rate (mg/kg BVV / h)	
	itude of e	ach input (mg / kg BW	/ h)	
0				
Timep	oint of fi	rst input (h)		
0				
Expos	sure time	(h) (Cannot be zero)		

1.2. Chemical Specific and Physiological inputs:

Chemical Specific Parameters

	Parameter	Value	Unit	Descript
1	k_abs	2.18	min*-1	Absorption rate
				constant
2	ke	0.23	min*-1	Elimination rate
				constant
3	MW	232.3	g/mol	Molecular weight
4	vdist	1.1	L/kg	Volume of
				distribution
4 H				

Physiological Parameters

	Parameter	Value	Unit	Descript	٠
1	BW	70	kg	Body weight	▼
•				•	



12

Single or multiple doses?

Single
 Multiple


0.5

STEPS IN REVERSE DOSIMETRY: BIOMONITORING INPUT


2.1. Model and Compartment

Selected model (Input tab): pbtk1cpt	
Select model compartment	
Ccompartment	

2.3. MCMC setting



2.2. Upload Biomonitoring data





(Re-)run MCMC

Once everything is uploaded and select, run the MCMC procedure

STEPS IN REVERSE DOSIMETRY: OUTPUT

3.1. Model diagnostic





How to interpret the diagnostic plots?

Trace-plot:

Shows you the sampled value for dose for each iteration. You would like to see trace-plots where the chains seem to 1) converge to a range (i.e. they stabilize) 2) visit the entire range of the resulting posterior distri

Trimmed trace-plot:

Using the left trace-plot, one can determine if enough iters discared (i.e. the burn in) or too many of them are discarde See it yourself: adjust the burn in on the left and see what

Autocorrelation:

Due to the nature of the sampling algorithm, there should be a high correlation between iterations within a chain. However as we compare more distant iterations (i.e. increase we should see the correlation going to 0.

If there seems to be a problem with any of these, try to: * increase the number of chains * increase the number of iterations per chain Complete MCMC runs for 4 chains representing different starting points

Trimmed MCMC runs after burn-in is discarded for the 4 chains, providing information about convergence and mixing of each chain


Autocorrelation plot showing how well the chains are mixing, with low autocorrelation indicating good mixing and convergence is achieved



STEPS IN REVERSE DOSIMETRY: OUTPUT

3.2. Posterior distribution of external dose

Density (trimmed chains)



- Two plots are shown, one showing the posterior distributions for each chain separately and the second one with all chains combined.
- Summary statistics of posterior distribution indicating that in this case the potential external dose is around 10.1, with a minimum of 9.7 and maximum of 10.6





....

Caffeine Case Study



CAFFEINE PARAMETERS

Exposure Settings

Dose unit

○ g ● mg ○ microg

Time unit

 \bigcirc d \bigcirc h \bigcirc min \bigcirc sec

Exposure Metric

● absolute (mg) O dose (mg/kg BW) O rate (mg/kg BW / h)

Magnitude of each input (mg)

```
270
```

Timepoint of first input (h)

0

Exposure time (h) (Cannot be zero)

0.01

Single or multiple doses?

Single

O Multiple

Time Scale

Upload custom time points

time steps /h

4

Simulation duration (h)

32

liver) = 0,08 L/min metabolism via CYP1A2
Exposure 270 mg oral

Chemical Specific Parameters

?

?

• Simulation with variability in CYP1A2 35% (Dorne et al., 2001)

CL in vivo = 0.2855 x 140 (million hepatocytes/g liver) x 2000 (g

Parameter Value Unit Description BP Blood plasma 1 ratio 2 cl hepatic 0.08 L/min Hepatic clearance 3 frac_abs_gut 0.8 Fractional absorption gut FUP 1 Fraction unbound 4 in plasma 5 GFR 0.06 L/min Glomerular filtration rate 6 0.01 min^-1 k abs Absorption rate constant (1st order) 7 MW 194.2 a/mol Molecular Weight

In vitro/QIVIVE US-EPA Comptox data


CLint = 0.2855 µL/min/million hepatocytes

8	P_adipose	0.263825	Blood tissue partition coefficient in the adipose
9	P_gut	0.943705	Blood tissue partition coefficient in the gut
10	P_kidney	1.025077	Blood tissue partition coefficient in the kidney
11	P_liver	1.013832	Blood tissue partition coefficient in the liver
12	P_rapid	1.002098	Blood tissue partition coefficient in the rapid compartment
13	P_slow	0.984071	Blood tissue partition coefficient in the slow compartment

Caffeine Forward Dosimetry

MC simulated CV trajectories

Median, lower-2.5% and upper 97.5% quantiles, pointwise in time




		2.5%-		97.5%-	
	0%-quantile	quantile	50%-quantile	quantile	100%-quantile
T-max (h)	2.50E+00	2.74E+00	3.00E+00	3.50E+00	3.75E+00
C-max (mg/L)	2.67E+00	2.95E+00	3.66E+00	4.73E+00	5.19E+00
Half-life (h)	5.00E+00	6.00E+00	8.00E+00	1.08E+01	1.20E+01
AUC (h * mg/L)	2.90E+01	3.49E+01	4.44E+01	5.36E+01	5.78E+01



Caffeine : Model Evaluation Predictions vs Experimental Data

MC simulated trajectory

Median, lower-2.5% and upper 97.5% quantiles, pointwise in time





Lelo et al., (1986) doi.org/10.1111/j.1365-2125.1986.tb05246.x

CAFFEINE- FORWARD DOSIMETRY


MC simulated trajectory Median, lower-2.5% and upper 97.5% quantiles, pointwise in time 3 **CV (mg/L)** 1-0 10 20 30 Ó Time (h)


Predicted vs observed concentrations. 10• **Predicted Value** 0.1-10 0.1 **Observed Value**



CAFFEINE – REVERSE DOSIMETRY

Using Caffeine time concentration profiles (Lelo et al., 1986) to recalculate exposure: reverse dosimetry Satisfactory redictions: Exposure 270 mg oral-Reverse dosimetry prediction median : 250 mg







Triangles are original data points.



NEW MODELS FORKPLATE

New Human and animal models

- Pregnancy/Gestational models
- Ontogenesis of enzymes
- Generic models for metabolites (detoxification/bioactivation)
- Reverse dosimetry models for metabolites/HBM/urine etc
- Bioaccumulation models (EFSA/ECHA)

Animal models

- Physiologically-based for cats, minipig, goat, turkey etc
- PBK/DEB models for salmon
- Web TKTD Tool to assess effect of pesticides on bird reproduction

ERA models

Generalise DEB and TKTD models across species



CONCLUSION AND FUTURE PERSPECTIVES







Reverse dosimetry models providing outputs for blood
 Need to include urine, parent compound and metabolites, other organs

TKPlate Training

Pilot planned for EFSA Staff and experts on 21-22 Nov 24 and Jan 25
 Moving towards recorded online training available open access ?

Moving towards application of TKPlate in EFSA panels
 Differences in NAM across EFSA panels: regulations, history
 Change management may be needed: from in vivo to NAMs

EC/International collaborations

PARC/ASPIS EU : follow up on models and data developed, uptake TKPlate
• Future <u>APRCA</u> case study on use of TKPlate for QIVIVE ?



ACKNOWLEDGEMENTS

- EFSA Staff: Jose Cortinas-Abrahantes, Fotios Spyropoulos, Djien Liem, Tobin Robinson, Georges Kass, Antony Smith, Jochem Louisse, Didier Verloo, Claudia Roncancio-Peña, Daniela Maurici, EFSA Senior Management
- Hans Bossier and Tobias , Open Analytics, Antwerp, Belgium
- Keyvin Darney, ANSES, Paris
- Leonie Lautz, Wageningen Agricultural Research Center, The Netherlands
- INERIS, Paris, France
- University of Utrecht, The Netherlands;
- ISS, Rome, Italy
- CERTARA Paris, London;
- Radboud University, Nijmegen, The Netherlands;
- Mario Negri, Milan, Italy
- RIVM, Bilthoven, The Netherlands
- Health and Safety Laboratory, UK
- US-EPA/NIEHS, USA





STAY CONNECTED

SUBSCRIBE TO

3

0

efsa.europa.eu/en/news/newsletters efsa.europa.eu/en/rss Careers.efsa.europa.eu – job alerts

LISTEN TO OUR PODCAST Science on the Menu – Spotify, Apple Podcast and YouTube

FOLLOW US ON TWITTER @efsa_eu (@plants_efsa (

@methods_efsa @animals_efsa FOLLOW US ON LINKEDIN Linkedin.com/company/efsa

in

 \bowtie

FOLLOW US ON INSTAGRAM @one_healthenv_eu CONTACT US efsa.europe.eu/en/contact/askefsa

